Amneal Pharmaceuticals, Inc. (NYSE:AMRX) marched up 0.3% compared to a 52-week low price of $6.77. The shares were last seen trading -3% lower, taking the closing price at $6.79 on 6/19/2019. At a recent session, the prices were hovering between $6.55 and $7.05. This company shares are 118.26% off its target price of $14.82 and the current market capitalization stands at $2.17B. The recent change has given its price a -34.52% deficit over SMA 50 and -72.26% deficit over its 52-week high. The stock witnessed -17.8% declines, -52.52% declines and -58.11% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AMRX’s volatility during a week at 5.64% and during a month it has been found around 6.09%.Amneal Pharmaceuticals, Inc. (AMRX) Top Holders
Institutional investors currently hold around $763 million or 96.5% in AMRX stock. Look at its top three institutional owners: Price T Rowe Associates Inc /Md/ owns $139.03 million in Amneal Pharmaceuticals, Inc., which represents roughly 6.41% of the company’s market cap and approximately 18.22% of the institutional ownership. Similar statistics are true for the second largest owner, Fosun International Ltd, which owns 19,552,001 shares of the stock are valued at $136.86 million. The third largest holder is Wellington Management Group Llp, which currently holds $111.35 million worth of this stock and that ownership represents nearly 5.13% of its market capitalization.
At the end of March reporting period, 80 institutional holders increased their position in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by some 3,818,103 shares, 71 decreased positions by 10,764,787 and 34 held positions by 94,442,235. That puts total institutional holdings at 109,025,125 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 750,666 shares while 22 institutional investors sold out their entire positions totaling 5,985,937 shares.Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Amneal Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP, Chief Scientific Officer Bhadauria Pradeep has acquired 7,000 shares of Amneal Pharmaceuticals, Inc. (AMRX) in the trading session dated May. 15, 2019. These shares are worth $59,360 and were traded at $8.48 each. The SEC filing shows that Todisco Joseph performed a purchase of 15,000 shares. The SVP, Specialty Commercial added these shares by way of transaction on May. 13, 2019. The company’s shares were assimilated at $9.88 per share worth to an investment of some $148,200 to the account of Todisco Joseph.
Exec VP, Comm Optns, BOYER ANDREW S, purchased 19,000 common shares of Amneal Pharmaceuticals, Inc. (AMRX) in the open market. In a transaction dated May. 13, 2019, the shares were bought at an average price of $9.46, giving away a sum of $179,740. After this purchase, 29,302 common shares of AMRX are directly owned by the insider, with total stake valued at $198,961.
In the transaction dated Mar. 12, 2019, a great number of shares acquired came courtesy the Executive Chairman; BISARO PAUL added a total of 17,000 shares at an average price of $11.97, amounting to approximately $203,490. The insider now directly owns 17,000 shares worth $115,430.
Several analysts have released their opinion on Amneal Pharmaceuticals, Inc. (NYSE:AMRX), with 2 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.36 average brokerage recommendation [T1].